TY  - JOUR

T1  - Nab-paclitaxel or docetaxel as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): a cost utility analysis in five European countries.

JO  - J Clin Oncol

PY  - 2008/05/20

AU  - Dranitsaris G

AU  - Lidgren M

AU  - Lundkvist J

AU  - Coleman RE

ED  - 

VL  - 26

IS  - 15_suppl

SP  - 6571

Y2  - 2025/10/10

ER  -